NEWS RELEASE 16 May 2016

Praxbind^™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa^{^®} (dabigatran etexilate)¹ Now Approved in Canada With Conditions

Read more on

Praxbind^™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa^{^®} (dabigatran etexilate)¹ Now Approved in Canada With Conditions

NEWS RELEASE 09 Sep 2015

Interim sub-group analysis shows the reversal agent idarucizumab* enables rapid initiation of emergency surgery in dabigatran-treated patients

Read more on

Interim sub-group analysis shows the reversal agent idarucizumab* enables rapid initiation of emergency surgery in dabigatran-treated patients

NEWS RELEASE 29 Aug 2015

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

Read more on

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

NEWS RELEASE 22 Jun 2015

New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications^1,2

Read more on

New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications^1,2

NEWS RELEASE 03 Mar 2015

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa^®), to EMA, FDA and Health Canada

Read more on

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa^®), to EMA, FDA and Health Canada

NEWS RELEASE 18 Dec 2014

New data presented at American Society of Hematology (ASH) shows specific antidote idarucizumab* reverses dabigatran-induced anticoagulation independent of age, and kidney function

Read more on

New data presented at American Society of Hematology (ASH) shows specific antidote idarucizumab* reverses dabigatran-induced anticoagulation independent of age, and kidney function

NEWS RELEASE 26 Nov 2014

New data presented at American Heart Association (AHA) show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

Read more on

New data presented at American Heart Association (AHA) show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

NEWS RELEASE 22 Sep 2014

Antidote for Rapid Reversal of Pradaxa^{^®} (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

Read more on

Antidote for Rapid Reversal of Pradaxa^{^®} (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

NEWS RELEASE 04 Sep 2014

Health Canada approves Pradaxa^{^®} for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE¹

Read more on

Health Canada approves Pradaxa^{^®} for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE¹

NEWS RELEASE 28 May 2014

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa^® (dabigatran etexilate mesylate) litigation

Read more on

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa^® (dabigatran etexilate mesylate) litigation

NEWS RELEASE 15 May 2014

As the Benefits and Safety of Pradaxa^® (dabigatran etexilate mesylate) are Once Again Confirmed, Boehringer Ingelheim Continues to Look for New Ways for Pradaxa^{^®} to Help More Patients

Read more on

As the Benefits and Safety of Pradaxa^® (dabigatran etexilate mesylate) are Once Again Confirmed, Boehringer Ingelheim Continues to Look for New Ways for Pradaxa^{^®} to Help More Patients

NEWS RELEASE 21 Mar 2014

Response to Recent Media Coverage of Pradaxa^® (dabigatran etexilate mesylate)

Read more on

Response to Recent Media Coverage of Pradaxa^® (dabigatran etexilate mesylate)

NEWS RELEASE 19 Nov 2013

Data from First Phase I Study of Antidote for Pradaxa^{^®} (dabigatran etexilate) Presented at American Heart Association Scientific Sessions

Read more on

Data from First Phase I Study of Antidote for Pradaxa^{^®} (dabigatran etexilate) Presented at American Heart Association Scientific Sessions

Search form

Praxbind™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa® (dabigatran etexilate)1 Now Approved in Canada With Conditions

Praxbind™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa® (dabigatran etexilate)1 Now Approved in Canada With Conditions

Interim sub-group analysis shows the reversal agent idarucizumab* enables rapid initiation of emergency surgery in dabigatran-treated patients

Interim sub-group analysis shows the reversal agent idarucizumab* enables rapid initiation of emergency surgery in dabigatran-treated patients

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2

New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

New data presented at American Society of Hematology (ASH) shows specific antidote idarucizumab* reverses dabigatran-induced anticoagulation independent of age, and kidney function

New data presented at American Society of Hematology (ASH) shows specific antidote idarucizumab* reverses dabigatran-induced anticoagulation independent of age, and kidney function

New data presented at American Heart Association (AHA) show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

New data presented at American Heart Association (AHA) show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

Antidote for Rapid Reversal of Pradaxa® (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

Antidote for Rapid Reversal of Pradaxa® (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

Health Canada approves Pradaxa® for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE1

Health Canada approves Pradaxa® for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE1

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

As the Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) are Once Again Confirmed, Boehringer Ingelheim Continues to Look for New Ways for Pradaxa® to Help More Patients

As the Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) are Once Again Confirmed, Boehringer Ingelheim Continues to Look for New Ways for Pradaxa® to Help More Patients

Response to Recent Media Coverage of Pradaxa® (dabigatran etexilate mesylate)

Response to Recent Media Coverage of Pradaxa® (dabigatran etexilate mesylate)

Data from First Phase I Study of Antidote for Pradaxa® (dabigatran etexilate) Presented at American Heart Association Scientific Sessions

Data from First Phase I Study of Antidote for Pradaxa® (dabigatran etexilate) Presented at American Heart Association Scientific Sessions

Praxbind^™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa^{^®} (dabigatran etexilate)¹ Now Approved in Canada With Conditions

Praxbind^™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa^{^®} (dabigatran etexilate)¹ Now Approved in Canada With Conditions

New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications^1,2

New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications^1,2

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa^®), to EMA, FDA and Health Canada

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa^®), to EMA, FDA and Health Canada

Antidote for Rapid Reversal of Pradaxa^{^®} (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

Antidote for Rapid Reversal of Pradaxa^{^®} (dabigatran etexilate) Progresses Into Next Stage of Clinical Investigation with Study in Canadian Patients

Health Canada approves Pradaxa^{^®} for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE¹

Health Canada approves Pradaxa^{^®} for the treatment of venous thromboembolism events (deep vein thrombosis [DVT] and pulmonary embolism [PE]), and for the prevention of recurrent DVT and PE¹

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa^® (dabigatran etexilate mesylate) litigation

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa^® (dabigatran etexilate mesylate) litigation

As the Benefits and Safety of Pradaxa^® (dabigatran etexilate mesylate) are Once Again Confirmed, Boehringer Ingelheim Continues to Look for New Ways for Pradaxa^{^®} to Help More Patients

As the Benefits and Safety of Pradaxa^® (dabigatran etexilate mesylate) are Once Again Confirmed, Boehringer Ingelheim Continues to Look for New Ways for Pradaxa^{^®} to Help More Patients

Response to Recent Media Coverage of Pradaxa^® (dabigatran etexilate mesylate)

Response to Recent Media Coverage of Pradaxa^® (dabigatran etexilate mesylate)

Data from First Phase I Study of Antidote for Pradaxa^{^®} (dabigatran etexilate) Presented at American Heart Association Scientific Sessions

Data from First Phase I Study of Antidote for Pradaxa^{^®} (dabigatran etexilate) Presented at American Heart Association Scientific Sessions